Given the regulatory role of Plk5 in cell cycle, this newly identify metastatic mutation could be an new addition to the known metastasis related genes [13] as an intervention target and biomarker in CCRCC [11, 12]. The gene discussed is PLK5; the disease is nonpapillary renal cell carcinoma.